2-Chlorodeoxyadenosine therapy for disseminated langerhans cell histiocytosis

Animesh D Pardanani, Robert L. Phyliky, Chin Yang Li, Ayalew Tefferi

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Objective: To evaluate the efficacy of 2-chlorodeoxy-adenosine (2-CDA), a purine nucleoside analogue, in treating disseminated Langerhans cell histiocytosis (LCH). Patients and Methods: We retrospectively reviewed the clinical records of 5 patients who were seen at our institution for histologically confirmed disseminated LCH, including 1 patient with central nervous system parenchymal involvement. These patients were treated consecutively with 2-CDA chemotherapy between December 1994 and January 2001. The patients ranged in age from 19 to 81 years, and the median pretreatment duration of disease was 23 months. Median follow-up after initiation of 2-CDA treatment was 33 months. 2-Chlorodeoxyadenosine was used as frontline therapy for 1 patient and as salvage therapy for the other patients. Patients generally received 0.7 mg/kg over 5 or 7 days; the median number of courses was 4. Results: Complete responses were achieved in 3 patients, including the patient with central nervous system disease, which, to our knowledge, has not been described previously. Two other patients achieved partial responses. The overall response rate was 100%. Toxic effects consisted mainly of myelosuppression; 1 patient developed dermatomal herpes zoster infection. Conclusion: Our experience confirms the reported efficacy of 2-CDA in the treatment of LCH; however, the optimal timing and schedule of therapy remain to be determined.

Original languageEnglish (US)
Pages (from-to)301-306
Number of pages6
JournalMayo Clinic Proceedings
Volume78
Issue number3
StatePublished - Mar 1 2003

Fingerprint

Cladribine
Langerhans Cell Histiocytosis
Adenosine
Therapeutics
Purine Nucleosides
Salvage Therapy
Poisons
Central Nervous System Diseases
Herpes Zoster

ASJC Scopus subject areas

  • Medicine(all)

Cite this

2-Chlorodeoxyadenosine therapy for disseminated langerhans cell histiocytosis. / Pardanani, Animesh D; Phyliky, Robert L.; Li, Chin Yang; Tefferi, Ayalew.

In: Mayo Clinic Proceedings, Vol. 78, No. 3, 01.03.2003, p. 301-306.

Research output: Contribution to journalArticle

@article{c57d5ea7c4274fcfbb5f4b4e778bdb70,
title = "2-Chlorodeoxyadenosine therapy for disseminated langerhans cell histiocytosis",
abstract = "Objective: To evaluate the efficacy of 2-chlorodeoxy-adenosine (2-CDA), a purine nucleoside analogue, in treating disseminated Langerhans cell histiocytosis (LCH). Patients and Methods: We retrospectively reviewed the clinical records of 5 patients who were seen at our institution for histologically confirmed disseminated LCH, including 1 patient with central nervous system parenchymal involvement. These patients were treated consecutively with 2-CDA chemotherapy between December 1994 and January 2001. The patients ranged in age from 19 to 81 years, and the median pretreatment duration of disease was 23 months. Median follow-up after initiation of 2-CDA treatment was 33 months. 2-Chlorodeoxyadenosine was used as frontline therapy for 1 patient and as salvage therapy for the other patients. Patients generally received 0.7 mg/kg over 5 or 7 days; the median number of courses was 4. Results: Complete responses were achieved in 3 patients, including the patient with central nervous system disease, which, to our knowledge, has not been described previously. Two other patients achieved partial responses. The overall response rate was 100{\%}. Toxic effects consisted mainly of myelosuppression; 1 patient developed dermatomal herpes zoster infection. Conclusion: Our experience confirms the reported efficacy of 2-CDA in the treatment of LCH; however, the optimal timing and schedule of therapy remain to be determined.",
author = "Pardanani, {Animesh D} and Phyliky, {Robert L.} and Li, {Chin Yang} and Ayalew Tefferi",
year = "2003",
month = "3",
day = "1",
language = "English (US)",
volume = "78",
pages = "301--306",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "3",

}

TY - JOUR

T1 - 2-Chlorodeoxyadenosine therapy for disseminated langerhans cell histiocytosis

AU - Pardanani, Animesh D

AU - Phyliky, Robert L.

AU - Li, Chin Yang

AU - Tefferi, Ayalew

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Objective: To evaluate the efficacy of 2-chlorodeoxy-adenosine (2-CDA), a purine nucleoside analogue, in treating disseminated Langerhans cell histiocytosis (LCH). Patients and Methods: We retrospectively reviewed the clinical records of 5 patients who were seen at our institution for histologically confirmed disseminated LCH, including 1 patient with central nervous system parenchymal involvement. These patients were treated consecutively with 2-CDA chemotherapy between December 1994 and January 2001. The patients ranged in age from 19 to 81 years, and the median pretreatment duration of disease was 23 months. Median follow-up after initiation of 2-CDA treatment was 33 months. 2-Chlorodeoxyadenosine was used as frontline therapy for 1 patient and as salvage therapy for the other patients. Patients generally received 0.7 mg/kg over 5 or 7 days; the median number of courses was 4. Results: Complete responses were achieved in 3 patients, including the patient with central nervous system disease, which, to our knowledge, has not been described previously. Two other patients achieved partial responses. The overall response rate was 100%. Toxic effects consisted mainly of myelosuppression; 1 patient developed dermatomal herpes zoster infection. Conclusion: Our experience confirms the reported efficacy of 2-CDA in the treatment of LCH; however, the optimal timing and schedule of therapy remain to be determined.

AB - Objective: To evaluate the efficacy of 2-chlorodeoxy-adenosine (2-CDA), a purine nucleoside analogue, in treating disseminated Langerhans cell histiocytosis (LCH). Patients and Methods: We retrospectively reviewed the clinical records of 5 patients who were seen at our institution for histologically confirmed disseminated LCH, including 1 patient with central nervous system parenchymal involvement. These patients were treated consecutively with 2-CDA chemotherapy between December 1994 and January 2001. The patients ranged in age from 19 to 81 years, and the median pretreatment duration of disease was 23 months. Median follow-up after initiation of 2-CDA treatment was 33 months. 2-Chlorodeoxyadenosine was used as frontline therapy for 1 patient and as salvage therapy for the other patients. Patients generally received 0.7 mg/kg over 5 or 7 days; the median number of courses was 4. Results: Complete responses were achieved in 3 patients, including the patient with central nervous system disease, which, to our knowledge, has not been described previously. Two other patients achieved partial responses. The overall response rate was 100%. Toxic effects consisted mainly of myelosuppression; 1 patient developed dermatomal herpes zoster infection. Conclusion: Our experience confirms the reported efficacy of 2-CDA in the treatment of LCH; however, the optimal timing and schedule of therapy remain to be determined.

UR - http://www.scopus.com/inward/record.url?scp=0037373124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037373124&partnerID=8YFLogxK

M3 - Article

C2 - 12630583

AN - SCOPUS:0037373124

VL - 78

SP - 301

EP - 306

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 3

ER -